Lesser responses to tefinostat were seen in undifferentiated AML patient subgroups M0/M1; although sensitivity was observed in occasional undifferentiated samples with inherent HDAC inhibitor sensitivity this manifested as equal sensitivity to tefinostat and CHR-8185. Here, HDAC9 is linked to acute myeloid leukemia.